Comparison of PCSK9 inhibitor evolocumab vs ezetimibe in statin‐intolerant patients: design of the goal achievement after utilizing an anti‐PCSK9 antibody in statin …
SE Nissen, RE Dent‐Acosta, RS Rosenson… - Clinical …, 2016 - Wiley Online Library
Statins are the accepted standard for lowering low‐density lipoprotein cholesterol (LDL‐C).
However, 5% to 10% of statin‐treated patients report intolerance, mostly due to muscle …
However, 5% to 10% of statin‐treated patients report intolerance, mostly due to muscle …
Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors
A Achimastos, T Alexandrides, D Alexopoulos… - Hormones, 2016 - Springer
Two proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, evolocumab and
alirocumab, have recently been approved by both the Food and Drug Administration (FDA) …
alirocumab, have recently been approved by both the Food and Drug Administration (FDA) …
Comparisons of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9I) versus Ezetimibe on Major Adverse Cardiovascular Events Amongst Patients with …
Background: Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9I) have potential
benefits against cardiovascular disease. The comparative risks of new-onset major adverse …
benefits against cardiovascular disease. The comparative risks of new-onset major adverse …
[HTML][HTML] Modern lipid management: a literature review
J Malik, H Shabeer, U Ishaq, H Chauhan Sr, HF Akhtar - Cureus, 2020 - ncbi.nlm.nih.gov
Pro-protein convertase subtilisin/Kexin type 9 (PCSK9) inhibitors are relatively new, non-
statin, lipid-lowering drugs that reduce low-density lipoprotein cholesterol (LDL-C) by 60 …
statin, lipid-lowering drugs that reduce low-density lipoprotein cholesterol (LDL-C) by 60 …
Effect of the PCSK9 inhibitor evolocumab on total cardiovascular events in patients with cardiovascular disease: a prespecified analysis from the FOURIER trial
SA Murphy, TR Pedersen, ZA Gaciong, R Ceska… - JAMA …, 2019 - jamanetwork.com
Importance The PCSK9 inhibitor evolocumab reduced low-density lipoprotein cholesterol
and first cardiovascular events in the Further Cardiovascular Outcomes Research With …
and first cardiovascular events in the Further Cardiovascular Outcomes Research With …
Is there enough evidence with evolocumab and alirocumab (antibodies to proprotein convertase substilisin-kexin type, PCSK9) on cardiovascular outcomes to use …
SA Doggrell, KA Lynch - Expert Opinion on Biological Therapy, 2015 - Taylor & Francis
Introduction: Statins alone often do not reduce LDL cholesterol levels sufficiently to given
maximum cardiovascular benefit. Thus, additional drugs are required to reduce the levels of …
maximum cardiovascular benefit. Thus, additional drugs are required to reduce the levels of …
[引用][C] Pcsk9-inhibition in routine clinical practice: real world data from Germany
E Waldmann, J Altenhofer, K Henze… - …, 2019 - atherosclerosis-journal.com
Methods: Lipid profiles were obtained (age 63±10 y, BMI 23.6±4.1 kg/m2, 49% male) before
and after 3-4 months treatment with PCSK9-i Results: 44% received Evolocumab 140mg …
and after 3-4 months treatment with PCSK9-i Results: 44% received Evolocumab 140mg …
[HTML][HTML] Effects of alirocumab on triglyceride metabolism: A fat-tolerance test and nuclear magnetic resonance spectroscopy study
T Metzner, DR Leitner, K Mellitzer, A Beck, H Sourij… - Biomedicines, 2022 - mdpi.com
Background: PCSK9 antibodies strongly reduce LDL cholesterol. The effects of PCSK9
antibodies on triglyceride metabolism are less pronounced. The present study aimed to …
antibodies on triglyceride metabolism are less pronounced. The present study aimed to …
[HTML][HTML] The patient journey with proprotein convertase subtilisin/kexin type 9 inhibitors in community practice
CK Bradley, P Shrader, RJ Sanchez… - Journal of clinical …, 2019 - Elsevier
Background Trials have demonstrated that proprotein convertase subtilisin/kexin type 9
(PCSK9) inhibitors are effective as an adjunct to statin therapy, but access and cost issues …
(PCSK9) inhibitors are effective as an adjunct to statin therapy, but access and cost issues …
New pharmacological approaches to target PCSK9
Abstract Purpose of Review Proprotein convertase subtilisin kexin 9 (PCSK9) plays a crucial
role in regulating circulating levels of LDL-C as a consequence of its ability to inhibit LDL …
role in regulating circulating levels of LDL-C as a consequence of its ability to inhibit LDL …